Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials

BACKGROUND: Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Creatine kinase (CK) levels and CK-related adverse events (AEs) in tofacitinib-treated patients with UC were evaluated. METHODS: Data were analyzed for three UC cohorts: Induction (phase 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Panaccione, Remo, Isaacs, John D., Chen, Lea Ann, Wang, Wenjin, Marren, Amy, Kwok, Kenneth, Wang, Lisy, Chan, Gary, Su, Chinyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298233/
https://www.ncbi.nlm.nih.gov/pubmed/32816215
http://dx.doi.org/10.1007/s10620-020-06560-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298233/
https://www.ncbi.nlm.nih.gov/pubmed/32816215
http://dx.doi.org/10.1007/s10620-020-06560-4

Ejemplares similares